<DOC>
	<DOCNO>NCT00425737</DOCNO>
	<brief_summary>To assess efficacy , immune response safety oral live attenuate HRV vaccine ( Rotarix ) healthy infant approximately 2 month age previously uninfected human rotavirus</brief_summary>
	<brief_title>Assess Efficacy , Immune Response &amp; Safety 2 Doses Oral Live Attenuated HRV Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant 6 12 week age time first vaccination . Written inform consent obtain parent guardian subject . Born normal gestation period ( 36 42 week ) . Use investigational nonregistered drug vaccine study vaccine within 30 day precede study vaccine placebo plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . ( Topical steroid allow . ) Use antibiotics period start 7 day dose vaccine ( ) end 7 day . Any clinically significant history chronic gastrointestinal disease serious medical condition determine investigator . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbated component vaccine . Gastroenteritis within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Household contact immunosuppressed individual pregnant woman . Abnormal stool pattern . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous confirm occurrence rotavirus gastroenteritis .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Oral live attenuate human rotavirus vaccine</keyword>
	<keyword>Gastroenteritis</keyword>
</DOC>